Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer

Journal:

Cancer Cell

Published:

2026-05-07

DOI:

10.1016/j.ccell.2026.04.005

Affiliations:

12

Authors:

36

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	15.000000 15.000000	0.42
Harvard Medical School (HMS), United States of America (USA)	12.666667 12.666667	0.35
Brigham and Women's Hospital (BWH), United States of America (USA)	3.000000	0.08
Bristol-Myers Squibb, United States of America (USA)	3.000000	0.08
Massachusetts General Hospital (MGH), United States of America (USA)	1.333333	0.04
Brookline High School, United States of America (USA)	1.000000	0.03

Interested in Oncology and Carcinogenesis?